Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Paclitaxel

Albumin-Bound Paclitaxel

Carboplatin

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Dose Escalation- EOS100850 Monotherapy: to confirm RP2D

EOS100850 and Pembrolizumab Combination Therapy: to confirm RP2D as combination

Dose Expansion- Monotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant as monotherapy

Dose Expansion - EOS100850 and Pembrolizumab Combination Therapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with pembrolizumab in melanoma and CRPC patients

Dose expansion - EOS100850 and Chemotherapy: to explore safety, PK, PD, and antitumor activity of inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC

Dose expansion - EOS100850 Monotherapy : to evaluate the safety, PD, and antitumor activity of inupadenant as monotherapy at the mono-RP2D in BMK-H participants in 4 disease-specific cohorts: NSCLC; HNSCC; EC; and other forms of cancer

EOS100850

Chemotherapy

Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.

First-in-Human Study of EOS100850 in Patients With Cancer

Phase I/Ib First-in-Human Study of EOS100850 as a Single Agent and in Combination With Pembrolizumab and/or Chemotherapy in Participants With Advanced Cancers

To define the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) of EOS100850 in patients receiving EOS100850

To assess safety and tolerability as measured by incidence and severity of AEs

Determined by inspection of the concentration-time profile

Assessment of preliminary efficacy of EOS100850

Merck Sharp & Dohme LLC

iTeos Therapeutics

Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Melanoma

Head and Neck Neoplasms

Lung Neoplasms

Antibodies

Antibodies, Monoclonal

Dostarlimab

Immunoglobulins

Participants will receive EOS-448 and pembrolizumab at every cycle

Participants will receive EOS-448 at every cycle and inupadenant on an ongoing basis

Participants will receive EOS-448 and dostarlimab at every cycle

Participants will receive dostarlimab at every cycle and inupadenant on an ongoing basis

Participants will receive EOS-448 and dostarlimab at every cycle and inupadenant on an ongoing basis

Participants with 1L mNSCLC will receive EOS-448 and dostarlimab and chemotherapies at every cycle

Participants with 1L mHNSCC CPS ≥ 20 will receive EOS-448 and dostarlimab at every cycle

Participants with 1L mHNSCC 1 \< CPS \< 20 will receive EOS-448 and dostarlimab at every cycle

EOS-448

pembrolizumab

inupadenant

SOC chemotherapies

iTeos Belgium SA

Clinical Trial Unit

Clinical Trial Unit Unit

Clinical Trials Unit

Iteos Clinical Trials

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.

The combinations evaluated will be:

* EOS-448 combined with pembrolizumab, an anti-PD-1 antibody
* EOS-448 combined with inupadenant an investigational adenosine A2A receptor antagonist
* EOS-448 combined with dostarlimab an anti-PD-1 antibody
* inupadenant combined with dostarlimab
* EOS-448 combined with inupadenant and dostarlimab
* EOS-448 combined with dostarlimab and standard of care chemotherapies in participants with NSCLC

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

A Multicenter, Open-Label, Phase I/II Study of EOS884448 (EOS-448) in Combination With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
First-in-Human Study of EOS100850 in Patients With Cancer	NCT03873883	Solid Tumor, Ad...	EOS100850 Pembrolizumab Chemotherapy	18 Years -	iTeos Therapeutics
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors	NCT05060432	Advanced Cancer Lung Cancer Head and Neck C... Melanoma	EOS-448 pembrolizumab inupadenant Dostarlimab SOC chemotherap...	18 Years -	iTeos Therapeutics

Spots Global Cancer Trial Database for eos100850

Every month we try and update this database with for eos100850 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for eos100850

Every month we try and update this database with for eos100850 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for eos100850 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.